Companies › Hasten Biopharmaceutical
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lerodalcibep (HST101) Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 3 | Hypercholesterolemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06568471 | Lerodalcibep (HST101) | Phase 3 | Hypercholesterolemia | Metabolic and endocrine | Feb 2026 |
Novartis AstraZeneca NewAmsterdam Pharma Verve Therapeutics Amgen Merck & Co. (MSD) Innovent Biologics (Suzhou) Regeneron Pharmaceuticals
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.